Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487
暂无分享,去创建一个
[1] J. Proost,et al. Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. , 1993, Journal of chromatography.
[2] K.,et al. Time Course of Action and Endotracheal Intubating Conditions of Org 9487, a New Short‐Acting Steroidal Muscle Relaxant; A Comparison with Succinylcholine , 1993, Anesthesia and analgesia.
[3] J. Proost,et al. Design of drugs for rapid onset , 1993 .
[4] P. Hennis,et al. Intubating conditions and onset of neuromuscular block of rocuronium (Org 9426); a comparison with suxamethonium , 1992, Acta anaesthesiologica Scandinavica.
[5] J. Wierda,et al. Clinical Pharmacokinetics of Neuromuscular Blocking Drugs , 1992, Clinical pharmacokinetics.
[6] K. Nakao,et al. ELEVATED ENDOTHELIN-1 LEVEL IN CEREBROSPINAL FLUID OF PATIENTS WITH SUBARACHNOID HEMORRHAGE , 1991 .
[7] Y. Ohta,et al. The neuromuscular effects of ORG9426 in patients receiving balanced anesthesia. , 1991, Anesthesiology.
[8] J. Wierda,et al. Dose‐Response Relation, Neuromuscular Blocking Action, Intubation Conditions, and Cardiovascular Effects of Org 9273, a New Neuromuscular Blocking Agent , 1991, Anesthesia and analgesia.
[9] L. Booij,et al. The neuromuscular blocking effect of Org 9426 , 1991, Anaesthesia.
[10] J. Wierda,et al. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl , 1991, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[11] William H. Press,et al. Numerical recipes , 1990 .
[12] K. Kuizenga,et al. Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent. , 1990, British journal of anaesthesia.
[13] W. Bowman,et al. Effects of a new neuromuscular blocking agent (Org 9426) in anaesthetized cats and pigs and in isolated nerve-muscle preparations. , 1989, British journal of anaesthesia.
[14] A. Kopman. Pancuronium, gallamine, and d-tubocurarine compared: is speed of onset inversely related to drug potency? , 1989, Anesthesiology.
[15] R. Hall,et al. Anesthetic interactions of midazolam and fentanyl: is there acute tolerance to the opioid? , 1988, Anesthesiology.
[16] W. Bowman,et al. Structure: action Relationships Among Some Desacetoxy Analogues of Pancuronium and Vecuronium in the Anesthetized Cat , 1988, Anesthesiology.
[17] S. Ágoston. Pharmacological profile of neuromuscular blocking agents: present and future trends. , 1988, Acta anaesthesiologica Belgica.
[18] N. Nussmeier,et al. An Assessment of Statistics , 1986 .
[19] C. Meistelman,et al. Disposition and Urinary Excretion of Vecuronium Bromide in Anesthetized Patients with Normal Renal Function or Renal Failure , 1986, Anesthesia and analgesia.
[20] A. Scaf,et al. Comparative Pharmacokinetics and Dynamics of Vecuronium and Pancuronium in Anesthetized Patients , 1986, Anesthesia and analgesia.
[21] H. Drexler,et al. [Modification of organ perfusion by calcium blocker and converting enzyme inhibitor in the conscious rat with heart failure]. , 1985, Klinische Wochenschrift.
[22] G. Scholtysik,et al. Effects of the New Calcium Antagonist PN 200–110 on the Myocardium and the Regional Peripheral Circulation in Anesthetized Cats and Dogs , 1984, Journal of cardiovascular pharmacology.
[23] Chingmuh Lee. Succinylcholine: Its past, present, and future , 1984 .
[24] D. Armstrong,et al. The kinetics of tubocurarine action and restricted diffusion within the synaptic cleft. , 1979, The Journal of physiology.
[25] John G. Wagner,et al. Fundamentals of Clinical Pharmacokinetics , 1975 .